- Home
- TNXP vs SRV Comparison
TNXP vs SRV Comparison
Compare TNXP & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- SRV
- Stock Information
- Founded
- TNXP 2007
- SRV 2007
- Country
- TNXP United States
- SRV United States
- Employees
- TNXP N/A
- SRV N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- SRV Finance Companies
- Sector
- TNXP Health Care
- SRV Finance
- Exchange
- TNXP Nasdaq
- SRV Nasdaq
- Market Cap
- TNXP 213.7M
- SRV 201.6M
- IPO Year
- TNXP N/A
- SRV N/A
- Fundamental
- Price
- TNXP $18.12
- SRV $42.64
- Analyst Decision
- TNXP Buy
- SRV
- Analyst Count
- TNXP 1
- SRV 0
- Target Price
- TNXP $70.00
- SRV N/A
- AVG Volume (30 Days)
- TNXP 734.4K
- SRV 33.9K
- Earning Date
- TNXP 11-07-2025
- SRV 01-01-0001
- Dividend Yield
- TNXP N/A
- SRV 13.38%
- EPS Growth
- TNXP N/A
- SRV N/A
- EPS
- TNXP N/A
- SRV N/A
- Revenue
- TNXP $9,831,000.00
- SRV N/A
- Revenue This Year
- TNXP $14.79
- SRV N/A
- Revenue Next Year
- TNXP $933.49
- SRV N/A
- P/E Ratio
- TNXP N/A
- SRV N/A
- Revenue Growth
- TNXP N/A
- SRV N/A
- 52 Week Low
- TNXP $6.76
- SRV $30.73
- 52 Week High
- TNXP $130.00
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- TNXP 34.78
- SRV 41.57
- Support Level
- TNXP $18.53
- SRV $42.76
- Resistance Level
- TNXP $18.96
- SRV $44.00
- Average True Range (ATR)
- TNXP 1.05
- SRV 0.72
- MACD
- TNXP 0.39
- SRV 0.06
- Stochastic Oscillator
- TNXP 24.31
- SRV 35.55
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.